Literature DB >> 27419822

Disability risk or unimproved symptoms following shunt surgery in patients with idiopathic normal-pressure hydrocephalus: post hoc analysis of SINPHONI-2.

Shigeki Yamada1, Teruo Kimura2, Naoto Jingami3, Masamichi Atsuchi4, Osamu Hirai5, Takahiko Tokuda6, Masakazu Miyajima7, Hiroaki Kazui8, Etsuro Mori9, Masatsune Ishikawa1.   

Abstract

OBJECTIVE The study aim was to assess the influence of presurgical clinical symptom severity and disease duration on outcomes of shunt surgery in patients with idiopathic normal-pressure hydrocephalus (iNPH). The authors also evaluated the cerebrospinal fluid tap test as a predictor of improvements following shunt surgery. METHODS Eighty-three patients (45 men and 38 women, mean age 76.4 years) underwent lumboperitoneal shunt surgery, and outcomes were evaluated until 12 months following surgery. Risks for poor quality of life (Score 3 or 4 on the modified Rankin Scale [mRS]) and severe gait disturbance were evaluated at 3 and 12 months following shunt surgery, and the tap test was also conducted. Age-adjusted and multivariate relative risks were calculated using Cox proportional-hazards regression. RESULTS Of 83 patients with iNPH, 45 (54%) improved by 1 point on the mRS and 6 patients (7%) improved by ≥ 2 points at 3 months following surgery. At 12 months after surgery, 39 patients (47%) improved by 1 point on the mRS and 13 patients (16%) improved by ≥ 2 points. On the gait domain of the iNPH grading scale (iNPHGS), 36 patients (43%) improved by 1 point and 13 patients (16%) improved by ≥ 2 points at 3 months following surgery. Additionally, 32 patients (38%) improved by 1 point and 14 patients (17%) by ≥ 2 points at 12 months following surgery. In contrast, 3 patients (4%) and 2 patients (2%) had worse symptoms according to the mRS or the gait domain of the iNPHGS, respectively, at 3 months following surgery, and 5 patients (6%) and 3 patients (4%) had worse mRS scores and gait domain scores, respectively, at 12 months after surgery. Patients with severe preoperative mRS scores had a 4.7 times higher multivariate relative risk (RR) for severe mRS scores at 12 months following surgery. Moreover, patients with severe gait disturbance prior to shunt surgery had a 46.5 times greater multivariate RR for severe gait disturbance at the 12-month follow-up. Patients without improved gait following the tap test had multivariate RRs for unimproved gait disturbance of 7.54 and 11.2 at 3 and 12 months following surgery, respectively. Disease duration from onset to shunt surgery was not significantly associated with postoperative symptom severity or unimproved symptoms. CONCLUSIONS Patients with iNPH should receive treatment before their symptoms become severe in order to achieve an improved quality of life. However, the progression of symptoms varies between patients so specific timeframes are not meaningful. The authors also found that tap test scores accurately predicted shunt efficacy. Therefore, indications for shunt surgery should be carefully assessed in each patient with iNPH, considering the relative risks and benefits for that person, including healthy life expectancy.

Entities:  

Keywords:  CSF = cerebrospinal fluid; INPHGS = iNPH grading scale; RR = relative risk; SINPHONI = study of iNPH on neurological improvement; gait disturbance; iNPH = idiopathic normal-pressure hydrocephalus; idiopathic normal pressure hydrocephalus; improvement rate; lumboperitoneal shunt; mRS = modified Rankin Scale

Mesh:

Year:  2016        PMID: 27419822     DOI: 10.3171/2016.5.JNS16377

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  6 in total

1.  Impact of Early Intervention for Idiopathic Normal Pressure Hydrocephalus on Long-Term Prognosis in Prodromal Phase.

Authors:  Yoshinaga Kajimoto; Masahiro Kameda; Akihiro Kambara; Kenji Kuroda; Shohei Tsuji; Yasutaka Nikaido; Ryuichi Saura; Masahiko Wanibuchi
Journal:  Front Neurol       Date:  2022-04-11       Impact factor: 4.086

2.  Timed up and go test at tap test and shunt surgery in idiopathic normal pressure hydrocephalus.

Authors:  Shigeki Yamada; Masatsune Ishikawa; Masakazu Miyajima; Madoka Nakajima; Masamichi Atsuchi; Teruo Kimura; Takahiko Tokuda; Hiroaki Kazui; Etsuro Mori
Journal:  Neurol Clin Pract       Date:  2017-04

3.  Guidelines for Management of Idiopathic Normal Pressure Hydrocephalus (Third Edition): Endorsed by the Japanese Society of Normal Pressure Hydrocephalus.

Authors:  Madoka Nakajima; Shigeki Yamada; Masakazu Miyajima; Kazunari Ishii; Nagato Kuriyama; Hiroaki Kazui; Hideki Kanemoto; Takashi Suehiro; Kenji Yoshiyama; Masahiro Kameda; Yoshinaga Kajimoto; Mitsuhito Mase; Hisayuki Murai; Daisuke Kita; Teruo Kimura; Naoyuki Samejima; Takahiko Tokuda; Mitsunobu Kaijima; Chihiro Akiba; Kaito Kawamura; Masamichi Atsuchi; Yoshihumi Hirata; Mitsunori Matsumae; Makoto Sasaki; Fumio Yamashita; Shigeki Aoki; Ryusuke Irie; Hiroji Miyake; Takeo Kato; Etsuro Mori; Masatsune Ishikawa; Isao Date; Hajime Arai
Journal:  Neurol Med Chir (Tokyo)       Date:  2021-01-15       Impact factor: 1.742

4.  Long-Term Prognosis of Cognitive Function in Patients With Idiopathic Normal Pressure Hydrocephalus After Shunt Surgery.

Authors:  Akihiro Kambara; Yoshinaga Kajimoto; Ryokichi Yagi; Naokado Ikeda; Motomasa Furuse; Naosuke Nonoguchi; Shinji Kawabata; Toshihiko Kuroiwa; Kenji Kuroda; Shohei Tsuji; Ryuichi Saura; Masahiko Wanibuchi
Journal:  Front Aging Neurosci       Date:  2021-01-20       Impact factor: 5.750

5.  Longitudinal morphological changes during recovery from brain deformation due to idiopathic normal pressure hydrocephalus after ventriculoperitoneal shunt surgery.

Authors:  Shigeki Yamada; Masatsune Ishikawa; Makoto Yamaguchi; Kazuo Yamamoto
Journal:  Sci Rep       Date:  2019-11-21       Impact factor: 4.379

Review 6.  Reconsidering Ventriculoperitoneal Shunt Surgery and Postoperative Shunt Valve Pressure Adjustment: Our Approaches Learned From Past Challenges and Failures.

Authors:  Shigeki Yamada; Masatsune Ishikawa; Madoka Nakajima; Kazuhiko Nozaki
Journal:  Front Neurol       Date:  2022-01-06       Impact factor: 4.003

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.